OPTIMIZERx Corp. (NASDAQ:OPRX), a health care technology firm, reported on Wednesday fourth-quarter sales of $32.32 million, up 14% year-over-year, beating the consensus of $30.36 million.

The company reported adjusted EPS of 30 cents, beating the analyst’s estimate of 27 cents.

Full-year revenue increased 29% year-over-year, reaching $92.1 million. The company’s gross profit climbed 23% in the fourth quarter to $22 million, with full-year gross profit totaling $59.4 million.

Adjusted EBITDA demonstrated significant growth, increasing 53% year-over-year in the fourth quarter to $8.8 million. For the full year, adjusted EBITDA reached $11.7 million.

OptimizeRx ended 2024 with $13.4 million in cash and cash equivalents, with net cash provided by operating activities totaling $4.9 million.

Also Read: What’s Going On With Baker Hughes Stock Today?

Key performance indicators reflected the company’s strong relationships with major pharmaceutical manufacturers.

• The top 20 pharmaceutical companies accounted for 64% of total revenue, with an average revenue per top manufacturer of $2.93 million, up from $2.4 million in 2023.
• The company maintained a 100% penetration rate among these top pharmaceutical clients and improved its net revenue retention to 121%, compared to 105% in the prior year.

Guidance: OptimizeRx expects continued growth in 2025, forecasting revenue of at least $100 million versus a consensus of $99.65 million and an adjusted EBITDA of at least $12 million.

OPRX Price Action: OptimizeRx stock is up 40.78% at $5.83 at publication Wednesday.

Read Next:

• Roche Further Boosts Obesity Pipeline With Zealand Pharma Deal Worth $5.3 Billion For Weight Loss Drugs

Photo: Shutterstock